Published in Cancer Res on June 01, 1983
Adenosine inhibition of lymphocyte-mediated cytolysis: possible role of cyclic adenosine monophosphate. Science (1975) 1.92
Subversion of host defense mechanisms by murine tumors. I. A circulating factor that suppresses macrophage-mediated resistance to infection. J Exp Med (1976) 1.56
Mouse virulence of K(L) antigen-containing strains of Escherichia coli. J Bacteriol (1969) 1.52
Mchanisms of antitumor action of Corynebacterium parvum: nonspecific tumor cell destruction at site of immunologically mediated sensitivity reaction to C. parvum. J Natl Cancer Inst (1975) 1.35
Inhibition of lymphocyte-mediated cytolysis by 3-deazaadenosine: evidence for a methylation reaction essential to cytolysis. Proc Natl Acad Sci U S A (1978) 1.35
Subversion of host defense mechanisms by murine tumors. II. Counter-influence of concomitant antitumor immunity. J Exp Med (1976) 1.17
Enzyme/prodrug gene therapy: comparison of cytosine deaminase/5-fluorocytosine versus thymidine kinase/ganciclovir enzyme/prodrug systems in a human colorectal carcinoma cell line. Cancer Res (1995) 1.13
Signaling pathways mediating insulin-stimulated glucose transport. Ann N Y Acad Sci (1999) 1.13
In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase. Cancer Res (1993) 1.06
5-Ethynyluracil (776C85): a potent modulator of the pharmacokinetics and antitumor efficacy of 5-fluorouracil. Proc Natl Acad Sci U S A (1993) 1.02
Observations on the nature of the determinants in anaerobic coryneforms which produce splenomegaly. J Reticuloendothel Soc (1981) 1.00
2-Fluoroadenosine 3':5'-monophosphate. A metabolite of 2-fluoroadenosine in mouse cytotoxic lymphocytes. J Biol Chem (1976) 0.99
Mechanisms of antitumor action of Corynebacterium parvum: replicating short-lived T cells as the mediators of potentiated tumor-specific immunity. J Reticuloendothel Soc (1976) 0.99
Chemotactic peptide induces cAMP elevation in human neutrophils by amplification of the adenylate cyclase response to endogenously produced adenosine. J Biol Chem (1989) 0.96
(1-Pyrenylmethyl)amino alcohols, a new class of antitumor DNA intercalators. Discovery and initial amine side chain structure-activity studies. J Med Chem (1990) 0.96
3-Deazaadenosine-induced disorganization of macrophage microfilaments. Proc Natl Acad Sci U S A (1985) 0.94
Reversible inhibition of lymphocyte mediated cytolysis by dimethyl sulfoxide (DMSO). J Immunol (1973) 0.93
Inhibition of lymphocyte-mediated cytolysis by adenosine analogs. Biochemical studies concerning mechanism of action. Biochem Pharmacol (1978) 0.92
Modulation of cyclic AMP metabolism by S-adenosylhomocysteine and S-3-deazaadenosylhomocysteine in mouse lymphocytes. Proc Natl Acad Sci U S A (1980) 0.91
Passive hemagglutination. II. Titration of antibody against determinants unique for aggregated denatured bovine serum albumin and further studies on gelatin. J Immunol (1970) 0.89
P-glycoprotein mediated resistance to 5'-nor-anhydro-vinblastine (Navelbine). Invest New Drugs (1995) 0.89
Studies on passive hemagglutination. I. Titration of "early" and "late" antibodies with tanned red cells sensitized with native or denatured bovine serum albumin. J Immunol (1969) 0.89
Antibody to Corynebacterium parvum in normal human and animal sera. Infect Immun (1977) 0.89
Some variations in lymphocyte freezing methods which do not affect cell viability. Tissue Antigens (1972) 0.88
Mechanisms of antitumor action of Corynebacterium parvum: the generation of cell-mediated tumor specific immunity. J Reticuloendothel Soc (1976) 0.87
2-[(arylmethyl) amino]-2-methyl-1,3-propanediol DNA intercalators. An examination of the effects of aromatic ring variation on antitumor activity and DNA binding. J Med Chem (1991) 0.86
Antagonism by taxol of effects of microtubule-disrupting agents on lymphocyte cAMP metabolism and cell function. Proc Natl Acad Sci U S A (1984) 0.83
Improved biodistribution, tumor targeting, and reduced immunogenicity in mice with a gamma 4 variant of Campath-1H. Proc Natl Acad Sci U S A (1995) 0.83
3-deazaadenosine inhibits leukocyte adhesion and ICAM-1 biosynthesis in tumor necrosis factor-stimulated human endothelial cells. J Immunol (1990) 0.82
Imidazo[4,5-c]pyridines (3-deazapurines) and their nucleosides as immunosuppressive and antiinflammatory agents. J Med Chem (1986) 0.82
Effects of calmodulin antagonists on immune mouse lymphocytes. Mol Pharmacol (1984) 0.81
3-Deazaadenosine 5'-triphosphate: a novel metabolite of 3-deazaadenosine in mouse leukocytes. Biochem Pharmacol (1989) 0.80
Iron chelates bind nitric oxide and decrease mortality in an experimental model of septic shock. Proc Natl Acad Sci U S A (1996) 0.80
Metabolism of tubercidin and formycin to their 3':5'-cyclic nucleotides in mammalian cells. J Biol Chem (1978) 0.80
Evaluation of arylmethylaminopropanediols by a novel in vitro pharmacodynamic assay: correlation with antitumor activity in vivo. Cancer Res (1990) 0.79
Xenogeneic ICAM-1 gene transfer suppresses tumorigenicity and generates protective antitumor immunity. Gene Ther (1996) 0.79
Ca2+ ionophore-induced cyclic adenosine-3',5'-monophosphate elevation in human neutrophils. A calmodulin-dependent potentiation of adenylate cyclase response to endogenously produced adenosine: comparison to chemotactic agents. Biochem Pharmacol (1991) 0.79
Effects of adenosine on neutrophil polarization induced by N-formyl-methionyl-leucyl-phenylalanine, sodium propionate and colchicine. Agents Actions (1989) 0.79
Inhibition of lymphocyte-mediated cytolysis by 2-fluoroadenosine--evidence for two discrete mechanisms of drug action. Biochem Pharmacol (1978) 0.78
Immunosuppressive effects of the S-adenosylhomocysteine hydrolase inhibitor, 3-deazaadenosine. J Immunopharmacol (1982) 0.78
Inhibition of lymphocyte-mediated cytolysis and cyclic AMP phosphodiesterase by erythro-9-(2-hydroxy-3-nonyl)adenine. J Immunopharmacol (1982) 0.78
Immune reaction of tumor-bearing mice to Propionibacterium acnes and the antitumor effect of the bacteria. Cancer Immunol Immunother (1982) 0.78
Pharmacokinetics and tissue distribution of the nonadecapeptide Moli1901 in rats and mice. Xenobiotica (2003) 0.78
Potentiation by homocysteine of adenosine-stimulated elevation of cellular adnosine 3',5'-monophosphate. Biochem Pharmacol (1979) 0.77
Taxol inhibits N-formyl-methionyl-leucyl-phenylalanine (FMLP)-induced human neutrophil polarization and H2O2 production while decreasing [3H]FMLP binding. Agents Actions (1987) 0.77
Targets of nitric oxide in a mouse model of liver inflammation by Corynebacterium parvum. Arch Biochem Biophys (1995) 0.77
Metabolic formation of nucleoside-modified analogues of S-adenosylmethionine. Biochem Biophys Res Commun (1979) 0.77
Inhibition of cyclic AMP phosphodiesterase by 5'-deoxy-5'-S-isobutylthioadenosine at biologically active concentrations of drug. Life Sci (1981) 0.77
3-Deazaadenosine. S-adenosylhomocysteine hydrolase-independent mechanism of action in mouse lymphocytes. J Biol Chem (1984) 0.77
Vinblastine fails to improve response of renal cancer to interferon alfa-n1: high response rate in patients with pulmonary metastases. J Clin Oncol (1991) 0.76
Inhibition of lymphocyte cyclic AMP phosphodiesterase and lymphocyte function by 5'-methylthioadenosine. Biochem Pharmacol (1982) 0.76
Inhibition of neutrophil adherence to endothelial cells by 3-deazaadenosine. Agents Actions (1989) 0.76
Efficacy of treatment with the iron (III) complex of diethylenetriamine pentaacetic acid in mice and primates inoculated with live lethal dose 100 Escherichia coli. J Clin Invest (1996) 0.75
Crisnatol mesylate: phase I dose escalation by extending infusion duration. Invest New Drugs (1991) 0.75
Inhibition of immune cell function by adenosine: biochemical studies. Adv Exp Med Biol (1979) 0.75
Effect of acyclovir on various murine in vivo and in vitro immunologic assay systems. Am J Med (1982) 0.75
Splenectomy vs. alpha interferon: a randomized study in patients with previously untreated hairy cell leukemia. Am J Hematol (1992) 0.75
A phase II study of crisnatol mesylate in patients with ovarian carcinoma. Invest New Drugs (1992) 0.75
Effects of adenosine deaminase inhibitors on lymphocyte-mediated cytolysis. Ann N Y Acad Sci (1985) 0.75
In vitro cytotoxicity expressed by cells active against established tumors in vivo. Cancer Res (1981) 0.75
Adenosine analogues as substrates and inhibitors of S-adenosylhomocysteine hydrolase in intact lymphocytes. Biochemistry (1980) 0.75
A randomized comparison of two doses of human lymphoblastoid interferon-alpha in hairy cell leukemia. Wellcome HCL Study Group. Blood (1991) 0.75
Phase I and clinical pharmacology trial of crisnatol (BWA770U mesylate) using a monthly single-dose schedule. Cancer Res (1988) 0.75
High-dose lymphoblastoid interferon in advanced renal cell carcinoma: an Eastern Cooperative Oncology Group Study. Cancer Treat Rep (1987) 0.75
Role of the GSA in medical education, 1957-1972. J Med Educ (1973) 0.75
Cell mediated immunity to Corynebacterium parvum and its role in tumor control. Dev Biol Stand (1978) 0.75
Cortical cytoplasm and configurational changes of RGC-6 cells exposed to cytochalasin B. Am J Anat (1975) 0.75
Phase I clinical and pharmacology study of 502U83 given as a 24-h continuous intravenous infusion. Cancer Chemother Pharmacol (1993) 0.75
Effect of purine synthesis inhibition on WiDr spheroids in vitro or on WiDr or colon 38 tumors in vivo. Complete growth inhibition but not regression. Biochem Pharmacol (1994) 0.75
Inhibition of lymphocyte function by 9-deazaadenosine. Biochem Pharmacol (1983) 0.75